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Background: Leptomeningeal carcinomatosis (LC) is a detrimental 
complication of patients with non–small-cell lung cancer (NSCLC). 
The effect of epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitors (TKIs) on the clinical outcome of these patients, 
particularly those with EGFR mutations, has not been studied yet.
Methods: We searched the database for lung cancer patients diag-
nosed from 2003 to 2010 in one Asian medical center. NSCLC 
patients who also had LC diagnosed by either cytology or brain neu-
roimaging studies were identiﬁed. The treatments and clinical out-
comes were reviewed.
Results: Of 5526 lung cancer patients, we identiﬁed 212 (3.8%) 
NSCLC patients with LC. Most patients (88.7%) had adenocarci-
noma histology, and 129 (60.9%) patients had been treated with at 
least one regimen of EGFR TKI before the diagnosis of LC. One 
hundred and twenty-four (58.5%) patients were treated with EGFR 
TKI, and 128 (60.4%) patients were treated with whole-brain radia-
tion therapy (WBRT) after the diagnosis of LC. The median over-
all survival was 4.5 months (95% conﬁdence interval, 3.5–7.3). 
Multivariate analysis suggested that EGFR TKI therapy, WBRT, and 
cytotoxic chemotherapy were independent predictors for longer sur-
vival. Mutational status of EGFR was evaluated in 101 patients, and 
75 mutations (74.3%) were detected. Among the 75 patients with 
EGFR mutations, EGFR TKI therapy and cytotoxic chemotherapy 
after diagnosis of LC remained the independent factors predictive of 
extended survival in the multivariate analysis.
Conclusions: Treatment of LC with EGFR TKI, cytotoxic chemo-
therapy, or WBRT in selected patients is associated with prolong sur-
vival period. These treatment options, especially EGFR TKIs, should 
be studied in patients with EGFR mutation-positive NSCLC and LC.
Key Words: Epidermal growth factor receptor tyrosine kinase inhib-
itor, Leptomeningeal carcinomatosis, Non–small-cell lung cancer, 
Prognosis, Whole-brain radiation therapy.
(J Thorac Oncol. 2015;10: 1754–1761)
Leptomeningeal carcinomatosis (LC) in patients with non–small-cell lung cancer (NSCLC) is not uncommon.1 
A previous report from our hospital revealed that the inci-
dence of LC proven by cytology was 0.7% in all lung can-
cer patients (including those with small-cell lung cancer) 
from 1992 to 2002.2 However, in our daily practice, most 
patients are diagnosed with LC through radiologic diagno-
sis, particularly magnetic resonance imaging (MRI), cor-
related to clinical symptoms such as headache and signs 
of increased intracranial pressure. As a consequence, the 
incidence is higher than previously reported. Given the 
improvement of systemic therapy for extracranial lesions of 
metastatic NSCLC, patients now live long enough to develop 
LC.3 Whole-brain radiation therapy (WBRT) and intrathecal 
chemotherapy (ITC) were the only treatment choice before 
the emergence of epidermal growth factor receptor tyrosine 
kinase inhibitors (EGFR TKIs).4
The development of EGFR TKIs, including geﬁtinib 
and erlotinib, has changed the treatment of patients with 
NSCLC in the past 10 years.5–7 Patients whose tumors harbor 
activating EGFR mutations, such as deletions in exon 19 and 
exon 21 L858R mutation, respond more frequently to EGFR 
TKI therapy.5,8–10 EGFR mutation status has been a predictor 
of improved survival in NSCLC patients with brain metas-
tases, but its role in patients with LC is not clear.11 Some 
authors have reported that EGFR TKIs were effective in treat-
ing LC in patients with EGFR mutations.12–14 In several ret-
rospective studies, EGFR TKI therapy for LC was found to 
prolong survival, but the impact of EGFR mutations was not 
clear because of the small number of patients who underwent 
EGFR gene testing.15–20 Geﬁtinib and erlotinib were available 
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commercially in Taiwan in 2003 and 2006, respectively, to 
treat metastatic lung cancer. In this study, we calculate the 
incidence of LC diagnosed by radiology and/or cytology/his-
tology in the era of EGFR TKI therapy. We also analyze the 
survival of patients with LC who underwent various local or 
systemic treatments.
MATERIALS AND METHODS
We screened patients diagnosed with lung cancer at 
National Taiwan University Hospital from January 2003 to 
December 2010 by linking data from two institutional data-
bases: the Cancer Registry and the Medical Coding Specialist 
Section of the Medical Information Management Ofﬁce at 
National Taiwan University Hospital, Taipei, Taiwan. Patients 
with cytologically or histologically diagnosed NSCLC and 
LC diagnosed by either cerebrospinal fluid (CSF) cytology or 
neuroimaging were identiﬁed. Regarding neuroimaging, LC 
was deﬁned as the presence of multifocal enhancing subarach-
noid nodules on gadolinium-enhanced brain MRI or contrast-
enhanced computed tomography (CT).
Medical records of these patients were reviewed. 
We evaluated the demographic data, histology type, EGFR 
mutation status, treatments before diagnosis of LC (includ-
ing EGFR TKIs, WBRT, and surgical resection of preexist-
ing brain metastases), initial presentation of LC, concurrent 
brain metastases status on diagnosis of LC, and the time from 
diagnosis of metastatic NSCLC by cytology/histology to 
the diagnosis of LC. Treatments after diagnosis of LC were 
recorded, including cytotoxic chemotherapy, EGFR TKIs, 
ITC, Ommaya reservoir implantation, and ventriculoperito-
neal (VP) shunt operation. All these treatments were at the 
discretion of treating physicians. The protocol of this study 
was approved by the Institutional Review Board of National 
Taiwan University Hospital.
Statistical Analysis
Overall survival (OS) time was determined from the 
date of diagnosis of LC (date of CSF cytology or neuroim-
aging examination) to the date of death or last follow-up. 
Patients who were discharged against medical advice with the 
intention to die at home according to Chinese custom in the 
ﬁnal stage of the dying process were recorded as a death event. 
Data were analyzed as a censor if a patient was unavailable to 
follow-up or survived beyond the ﬁnal date of medical record 
access (December 31, 2011).
The OS was estimated by the Kaplan–Meier method, 
and the differences between the study groups were com-
pared by the log-rank test. Cox’s proportional hazard model 
was used to estimate the univariate or adjusted hazard ratios 
and associated 95% conﬁdence intervals (CI) to detect differ-
ences of OS. Multivariate analyses were performed by using 
the Cox’s proportional hazard model, adjusted for gender, 
age, smoking status, and previous EGFR TKI therapy status 
of patients. Subgroup analyses focused on (1) patients with 
EGFR mutations and (2) EGFR TKI–pretreated patients who 
received another EGFR TKI therapy for LC or rechallenge of 
the previous EGFR TKI for LC with an EGFR TKI free inter-
val of at least 6 months. Two-sided p values less than or equal 
to 0.05 were considered statistically signiﬁcant. All analyses 
were performed by SAS statistics software, Version 9.3 (SAS 
Institute Inc., Cary, NC).
RESULTS
Of the total of 5526 lung cancer patients screened, 
212 (3.8%) patients with NSCLC and LC were identiﬁed. 
The median patient age was 56 years (range, 29–87 yr), 127 
(59.9%) were female, 155 (73.1%) were never smokers, and 
188 (88.7%) had adenocarcinoma histology. One hundred 
and twenty-nine (60.9%) patients had undergone EGFR TKI 
therapy before the diagnosis of LC. Most patients (47.6%) 
were diagnosed with LC by MRI and 19 (9.0%) patients 
were diagnosed with LC by a positive CSF cytology study 
(Table 1). The median time from diagnosis of metastatic 
disease to diagnosis of LC was 10.7 months (range, −1.5 
to 55.5), and 48 (22.6%) patients had LC at initial diagno-
sis of metastatic NSCLC. Sixty-ﬁve (30.7%) patients had 
brain metastases on diagnosis of LC (Table 2). The most 
common symptoms on diagnosis were headache (49.0%), 
nausea/vomiting (41.5%), dizziness (24.1%), conscious 
change (21.7%), neurological deﬁcit (17.9%), unsteady gait 
(14.2%), and seizure (8.0%). Fifteen (7.1%) patients were 
asymptomatic on diagnosis of LC.
Regarding local treatment for LC, 128 (60.4%) patients 
underwent WBRT, 23 (11.8%) patients underwent ITC, 31 
(14.6%) patients underwent VP shunt operation, and 22 
(10.4%) patients underwent Ommaya reservoir implantation. 
Regarding systemic therapy, 124 (58.5%) patients underwent 
EGFR TKI therapy, 22 (10.4%) patients underwent platinum-
based cytotoxic chemotherapy, and 56 (26.4%) patients under-
went nonplatinum-based cytotoxic chemotherapy after LC 
diagnosis (Table 2).
A total of 142 patients died, and 10 patients were 
still alive at the cut-off date. The median follow-up time 
was 2.5 months (range, 0–34.3), and the median survival 
was 4.5 months (95% CI, 3.5–7.3; Fig. 1). The median sur-
vival of different diagnostic modalities among CT, MRI, 
and CSF cytology were 6.5, 3.7, and 4.3 months, respec-
tively (p = 0.268). Regarding systemic therapy, patients 
who received EGFR TKI therapy after LC diagnosis had 
longer OS than patients who did not (median 9.5 versus 
1.7 months, p < 0.001; Fig. 2A). Patients who underwent 
cytotoxic chemotherapy also had longer OS (median, 10.2 
versus 2.8 months, p <  0.001; Fig. 2B). As for local ther-
apy, patients who underwent WBRT for LC survived lon-
ger (median, 8.4 versus 1.8 months, p < 0.001; Fig. 2C), but 
patients who underwent ITC (Fig. 2D), VP shunt operation, 
and Ommaya reservoir implantation did not. In a multivari-
ate analysis adjusted for gender, age (≥70 or <70), smoking 
status, EGFR TKI naive or EGFR TKI pretreated, VP shunt 
operation, Ommaya reservoir implantation, EGFR TKI ther-
apy after LC diagnosis, cytotoxic chemotherapy, and WBRT 
remained predictors of prolonged survival (Table 3).
One hundred and one patients had known EGFR muta-
tion status, and 75 (74.3%) had EGFR mutations (com-
mon activating mutations of deletions in exon 19 and exon 
21 L858R mutation were detected in 68 patients). Among 
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these patients, 52 (69.3%) patients underwent WBRT, 49 
(65.3%) patients underwent EGFR TKI therapy, and 32 
(42.7%) patients underwent cytotoxic chemotherapy. The 
median survival in patients who underwent EGFR TKI therapy 
for LC was longer than in patients who did not (median, 10.9 
versus 2.3 months, p < 0.001; Fig. 3A). Patients who under-
went cytotoxic chemotherapy also had longer OS (median, 
13.3 versus 4.1 months, p = 0.017; Fig. 3B). The median sur-
vival in patients who underwent WBRT for LC was longer 
than in patients who did not (median, 10.9 versus 2.4 months, 
p = 0.002; Fig. 3C). In multivariate analysis, EGFR TKI 
therapy and cytotoxic chemotherapy remained the predictors 
of prolonged survival (Supplemental Table 1, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A893).
In a subgroup of EGFR TKI–pretreated patients in 
whom LC developed and who underwent another EGFR TKI 
therapy (n = 28) or rechallenge of previous EGFR TKI therapy, 
with an EGFR TKI free interval of at least 6 months (n = 6), 
30 (88.2%) patients underwent geﬁtinib as EGFR TKI therapy 
before diagnosis of LC. Among these patients, 21 (61.8%) 
patients underwent WBRT, and 31 (91.2%) patients under-
went erlotinib therapy for LC. The median treatment dura-
tion was 2.0 months (range, 0.1–15.6). Clinical response was 
recorded in 22 (64.7%) patients. The median survival of these 
patients was 9.5 months (95% CI, 4.4–13.3; Supplemental 
Fig. 1, Supplemental Digital Content 2, http://links.lww.com/
JTO/A894).
DISCUSSION
In this current single institutional study, we demon-
strated that the incidence of LC in NSCLC patients between 
2003 and 2010 was 3.8% among all registered lung can-
cer patients. The incidence of LC in patients with EGFR 
mutation-positive or EGFR wild-type NSCLC was not cal-
culated here because not all patients had known EGFR muta-
tion status. The time from diagnosis of metastatic disease 
to diagnosis of LC was widely distributed. Some patients 
developed LC upon the diagnosis of metastatic disease, and 
some patients developed LC late after a long period of EGFR 
TKI therapy. This indicated that the biology of the tumors 
was different. The standard of diagnosis of LC is the pres-
ence of malignant cells in a CSF specimen. Gadolinium-
enhanced MRI is the preferred choice of neuroimaging study 
to diagnose LC, and contrast-enhanced CT is the alternative 
choice, despite its lower sensitivity and speciﬁcity.21 Many 
patients with LC cannot cooperate with lumbar puncture for 
CSF study or with a time-consuming MRI study because of 
neurologic symptoms, change in consciousness, or seizures. 
Contrast-enhanced CT could be a rapid diagnostic tool for 
these patients. In this study, 92 patients were diagnosed 
with LC by a contrast-enhanced CT. Among these patients, 
33 (35.9%) patients had concomitant CSF study or MRI 
study to conﬁrm the diagnosis of LC. We included all these 
acceptable diagnostic tools to minimize the bias of patient 
selection and to reflect our daily practice.
TABLE 1. Patient Characteristics
Variable
Total 212 (100)
Gender, N (%) Male 85 (40.1)
Female 127 (59.9)
Age (yr) Median (range) 56 (29–87)
Smoking, N (%) Never smoker 155 (73.1)
Histology, N (%) Adenocarcinoma 188 (88.7)
Nonadenocarcinoma 24 (11.3)




EGFR mutation, N (%) Unknown 111 (53.3)
Wild type 26 (12.3)
19 deletion or L858R 68 (31.1)
Other mutationsa 7 (3.3)
Brain metastases before LC 
diagnosis, N (%)
Presence 89 (42.0)
Previous WBRT before LC 
diagnosis, N (%)
Presence 54 (25.5)
Previous operation for brain 
metastases, N (%)
Presence 10 (4.7)
Previous EGFR TKI therapy  
before LC diagnosis, N (%)
Presence 129 (60.9)
aOther mutations included three exon 20 insertion, two exon 21 L861Q mutation, 
one exon 18 G719A mutation, and one exon 21 K860E mutation.
EGFR, epidermal growth factor receptor; LC, leptomeningeal carcinomatosis; TKI, 
tyrosine kinase inhibitor.
TABLE 2. Clinical Presentation and Treatment of LC
Variable
Time from diagnosis  
of metastatic lung cancer  
to LC (mo)
Median (range) 10.7 (-1.5 to 55.5)
Sequence of LC and metastatic 
lung cancer, N (%)




Modality of LC diagnosis, N (%) MRI 101 (47.6)
CT 92 (43.4)
CSF cytology 19 (9.0)
Concurrent brain  
metastases, N (%)
Presence 65 (30.7)
Local treatment for LC, N (%) WBRT 128 (60.4)
ITC 25 (11.8)
VP shunt 31 (14.6)
Ommaya reservoir 22 (10.4)







EGFR TKI therapy, N (%) Geﬁtinib 64 (30.2)
Erlotinib 68 (32.1)
Afatinib 7 (3.3)
LC, leptomeningeal carcinomatosis; MRI, magnetic resonance image; CT, 
computed tomography; CSF, cerebrospinal fluid; WBRT, whole-brain radiation therapy; 
ITC, intrathecal chemotherapy; VP shunt, ventriculoperitoneal shunt; EGFR, epidermal 
growth factor receptor; TKI, tyrosine kinase inhibitor.
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The median survival of this study cohort was 4.5 months. 
In other single institutional studies of the era of EGFR TKI 
therapy, the median survival ranged from 3.0 to 6.0 months 
in the overall study populations.15–20 There was a trend toward 
a longer survival in patients who were diagnosed with LC by 
CT in this study. In our hospital, physicians use CT to follow-
up patients with metastatic NSCLC, and many patients were 
diagnosed with LC by contras-enhanced CT early, while he 
or she was asymptomatic or having minimal symptoms. The 
survival was thus longer than previously reported. There was 
no difference in survival with respect to age. One reason is 
that only 31 patients were older than 70 years, and the number 
was relatively small. Another reason is that in patients with 
LC, performance status was a better predictor of survival than 
age as mentioned in another study.17 The role of various local 
treatments for LC and their contribution to OS are controver-
sial. Some authors have demonstrated that WBRT for LC is a 
predictor of better survival, but other authors have not.15–17,19,20 
The role of ITC is controversial as well.17,19,20,22 In this study, 
60.4% and 11.8% of patients underwent WBRT and ITC for 
fIGURE 1. Overall survival of all patients from 
diagnosis of leptomeningeal carcinomatosis to 
death.
TABLE 3. Univariate and Multivariate Analysis for Survival in Overall Population
Variables
Univariate Multivariate
HR (95% CI) P Value HR (95% CI) P Value
Age
  <70 1.0
  ≥70 1.40 (0.89–2.21) 0.150
Sex
  Female 1.0 1.0
  Male 1.57 (1.12–2.20) 0.008 1.28 (0.82–1.98) 0.276
Smoking
  Never smoker 1.0 1.0
  Current or former smoker 1.53 (1.07–2.20) 0.021 1.19 (0.75–1.87) 0.466
EGFR TKI therapy before LC
  No 1.0 1.0
  Yes 1.63 (1.14–2.34) 0.007 1.23 (0.84–1.79) 0.287
Treatment for LC
EGFR TKI 0.34 (0.24–0.48) <0.001 0.33 (0.23–0.47) <0.001
WBRT 0.38 (0.27–0.54) <0.001 0.39 (0.27–0.56) <0.001
ITC 0.90 (0.54–1.48) 0.667
Chemotherapy 0.55 (0.39–0.78) <0.001 0.53 (0.36–0.77) <0.001
VP shunt operation 0.64 (0.40–1.02) 0.059
Ommaya reservoir 0.94 (0.56–1.59) 0.811
HR, hazard ratio; CI, conﬁdence interval; LC, leptomeningeal carcinomatosis; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; WBRT, whole-brain 
radiation therapy; ITC, intrathecal chemotherapy; VP shunt, ventriculoperitoneal shunt.
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LC, respectively, and we demonstrated that WBRT was an 
independent predictor of prolonged survival, but ITC was not. 
The treatment protocol of ITC, however, was not uniﬁed in 
our hospital.
Regarding systemic therapy for LC, in case reports of 
various clinical scenarios, geﬁtinib and erlotinib have been 
proposed as effective treatments for LC.14,23–27 Erlotinib was 
found to achieve a higher CSF concentration, and some physi-
cians administered high-dose erlotinib to treat LC.28–32 In these 
retrospective studies, EGFR TKI therapy conferred a survival 
beneﬁt. Because only a few patients underwent EGFR gene 
testing, the survival beneﬁt of EGFR TKI therapy for patients 
with EGFR mutations, however, is not clear. In this study, 
EGFR TKI therapy prolonged survival in patients whether or 
not they had EGFR TKI therapy before the diagnosis of LC. In 
patients with EGFR mutations, those who underwent EGFR 
TKI therapy had a signiﬁcantly longer survival time, with a 
median survival of 10.9 months. To the best of our knowledge, 
this was the largest cohort of LC patients with a known EGFR 
mutation status. As for systemic cytotoxic chemotherapy, the 
impact on survival beneﬁt is debatable.16,17,19,20 In our series, 
patients who underwent cytotoxic chemotherapy for LC had 
longer survival both in the overall population and in the sub-
group of patients with EGFR mutations. In Taiwan and East 
Asia, the prevalence of EGFR mutation-positive NSCLC is 
higher than in Western countries.5,6 In the era of EGFR TKI 
therapy, patients with EGFR mutations underwent standard 
ﬁrst-line treatment with an EGFR TKI, such as geﬁtinib, 
erlotinib, or afatinib.33–38 A retrospective study revealed that 
the incidence of central nervous system (CNS) recurrence 
increased after an initial response to geﬁtinib.3 In this study, 
most patients were diagnosed with LC after a median period 
of 10.7 months of treatment for metastatic lung cancer, and 
most of these patients had undergone prior EGFR TKI ther-
apy. Takenaka et al.23 report on a patient on geﬁtinib therapy in 
whom LC developed but who responded to erlotinib therapy. A 
retrospective study compared the efﬁcacies of EGFR TKIs for 
treating LC, and erlotinib was shown to have a better control 
rate (64.3%, deﬁned as cytologic negative conversion) of LC 
than did geﬁtinib.39 EGFR T790M resistance mutation is the 
fIGURE 2. Kaplan–Meier analysis showing overall survival of all patients who (A) received (red) or did not receive (blue) 
epidermal growth factor receptor tyrosine kinase inhibitor therapy after diagnosis of leptomeningeal carcinomatosis (LC); (B) 
received (red) or did not receive (blue) cytotoxic chemotherapy after diagnosis of LC; (C) received (red) or did not receive (blue) 
whole-brain radiation therapy after diagnosis of LC; (D) received (red) or did not receive (blue) intrathecal chemotherapy after 
diagnosis of LC.
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main mechanism of acquired resistance to EGFR TKI therapy, 
which accounts for 60% of the patients who develop acquired 
resistance to EGFR TKI therapy.40,41 However, a retrospective 
study revealed that in patients in whom acquired resistance to 
prior EGFR TKI therapy developed, acquired EGFR T790M 
resistance mutation was detected in only 1 out of 20 CSF spec-
imens (5%).42 In this study, we identiﬁed 34 patients who had 
undergone EGFR TKI therapy for metastatic disease before 
the diagnosis of LC who subsequently underwent another 
EGFR TKI therapy or rechallenge of a previous therapy, with 
an intervening period of at least 6 months, after the diagnosis 
of LC. Most patients in this subgroup were geﬁtinib pretreated 
and underwent erlotinib therapy for LC. The median survival 
was 9.5 months. This result implies that physicians should not 
exclude patients pretreated with an EGFR TKI from another 
EGFR TKI therapy or a rechallenge therapy after diagnosis 
with LC.
This retrospective study had several limitations. There 
were many censors in the survival curve. Among these 
patients, 60 patients did not return to our hospital after the last 
day of follow-up. Because our hospital is a tertiary referral 
medical center, many patients died at other hospitals and did 
not have formal records of death. The censors were randomly 
distributed and did not influence the results. The performance 
status was not recorded in this study, which was regarded as 
a good prognostic factor.17 However, in a retrospective study, 
EGFR TKI therapy was still an independent good prognostic 
factor regardless of performance status.17 In patients with cer-
tain clinical features or whose tumors harbor activating EGFR 
mutations, EGFR TKI therapy may provide a clinical ben-
eﬁt in patients with poor performance status.43,44 Physicians 
should not exclude patients from EGFR TKI therapy accord-
ing to performance status alone. The treatment modalities 
and the sequence of treatment for LC were heterogeneous, 
and we identiﬁed prognostic factors only by the presence of 
speciﬁc treatment. The synergistic effects of different treat-
ments cannot be evaluated here.45 Responses to various treat-
ment modalities and the durations of response were difﬁcult 
to evaluate, and it was difﬁcult to attribute tumor response 
to one treatment modality while a patient was undergoing 
two or more treatment modalities. Patients may survive lon-
ger because of effective control of extracranial disease with 
EGFR TKI therapy or cytotoxic chemotherapy and effective 
control of brain metastases with WBRT. The true effects of 
fIGURE 3. Kaplan–Meier analysis showing overall survival of patients with epidermal growth factor receptor (EGFR) mutations 
who (A) received (red) or did not receive (blue) EGFR tyrosine kinase inhibitor therapy after diagnosis of leptomeningeal carci-
nomatosis; (B) received (red) or did not receive (blue) cytotoxic chemotherapy after diagnosis of LC; (C) received (red) or did 
not receive (blue) whole-brain radiation therapy after diagnosis of leptomeningeal carcinomatosis.
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EGFR TKI therapy, cytotoxic chemotherapy, and WBRT on 
LC control cannot be concluded here. We used OS to mea-
sure the clinical beneﬁts, which might not truly represent the 
tumor response. Other potential predictors of better survival 
outcome, such as CSF protein and white blood cell counts, 
were not evaluated in this study because only 9% of the study 
population underwent initial CSF study.17
The novel EGFR TKI afatinib was approved by regula-
tory authorities in 2013, and its effectiveness in treating CNS 
metastases (brain metastases and LC) has been suggested in 
a retrospective study.46 In a case report, afatinib in combina-
tion with cetuximab was effective in treating LC.47 In addi-
tion, novel EGFR TKIs designed to overcome acquired EGFR 
T790M resistance mutation, such as AZD9291 and rociletinib 
(CO-1686), are under clinical development, and activities 
against CNS metastases have been reported.48–50 These novel 
agents and combination therapy may be effective in treating 
LC in the future.
In conclusion, in the era of EGFR TKI therapy, treat-
ment of patients with LC using EGFR TKI, cytotoxic che-
motherapy, and WBRT has been shown to prolong survival. 
Prospective study is still warranted to evaluate the impacts of 
novel EGFR TKIs, such as afatinib, AZD9291, and rociletinib 
on survival outcomes, especially for patients whose tumors 
harbor EGFR mutations.
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